Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin-induced insulin-deficient diabetic mice by restoring brown adipose tissue function

J. H. Kim, K. H. Bae, Y. K. Choi, Y. Go, M. Choe, Y. H. Jeon, H. W. Lee, S. H. Koo, J. W. Perfield, Robert Harris, I. K. Lee, Keun Gyu Park

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Aim: To investigate the effects of LY2405319, an analogue of fibroblast growth factor 21 (FGF21), on glucose homeostasis in streptozotocin (STZ)-induced insulin-deficient mice (STZ mice). Methods: Nine-week-old male C57BL/6J mice were administered a single intraperitoneal injection of STZ (150mg/kg). Oneweek later, after confirmation of hyperglycaemia, saline or LY2405319 (5mg/kg) was injected subcutaneously daily for 4weeks. Changes in glucose homeostasis, energy metabolism and brown adipose tissue (BAT) function were assessed. Results: The STZ mice had elevated blood glucose and reduced plasma FGF21 levels, impaired glucose uptake in the BAT, and BAT mitochondria with absent or swollen cristae and fewer lipid vacuoles. LY2405319 significantly reduced blood glucose levels and this was associated with increased BAT glucose uptake and changes in gene expression and morphology, indicating improved mitochondrial lipid metabolism in the BAT. Importantly, the ability of LY2405319 to lower blood glucose in STZ mice was compromised after removing interscapular BAT. Conclusions: Our results show that LY2405319 reduces blood glucose levels in insulin-deficient diabetes by improving BAT metabolism. Additional studies investigating the therapeutic potential of FGF21 for the treatment of type 1 diabetes are warranted.

Original languageEnglish
Pages (from-to)161-169
Number of pages9
JournalDiabetes, Obesity and Metabolism
Volume17
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Brown Adipose Tissue
Streptozocin
Blood Glucose
Insulin
Glucose
Homeostasis
Vacuoles
fibroblast growth factor 21
Intraperitoneal Injections
Type 1 Diabetes Mellitus
Inbred C57BL Mouse
Lipid Metabolism
Hyperglycemia
Energy Metabolism
Mitochondria
Lipids
Gene Expression
Therapeutics

Keywords

  • Antidiabetic drug
  • Glucose uptake
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin-induced insulin-deficient diabetic mice by restoring brown adipose tissue function. / Kim, J. H.; Bae, K. H.; Choi, Y. K.; Go, Y.; Choe, M.; Jeon, Y. H.; Lee, H. W.; Koo, S. H.; Perfield, J. W.; Harris, Robert; Lee, I. K.; Park, Keun Gyu.

In: Diabetes, Obesity and Metabolism, Vol. 17, No. 2, 01.02.2015, p. 161-169.

Research output: Contribution to journalArticle

Kim, J. H. ; Bae, K. H. ; Choi, Y. K. ; Go, Y. ; Choe, M. ; Jeon, Y. H. ; Lee, H. W. ; Koo, S. H. ; Perfield, J. W. ; Harris, Robert ; Lee, I. K. ; Park, Keun Gyu. / Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin-induced insulin-deficient diabetic mice by restoring brown adipose tissue function. In: Diabetes, Obesity and Metabolism. 2015 ; Vol. 17, No. 2. pp. 161-169.
@article{2ec00a778d6b43b5ba23114c2661396e,
title = "Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin-induced insulin-deficient diabetic mice by restoring brown adipose tissue function",
abstract = "Aim: To investigate the effects of LY2405319, an analogue of fibroblast growth factor 21 (FGF21), on glucose homeostasis in streptozotocin (STZ)-induced insulin-deficient mice (STZ mice). Methods: Nine-week-old male C57BL/6J mice were administered a single intraperitoneal injection of STZ (150mg/kg). Oneweek later, after confirmation of hyperglycaemia, saline or LY2405319 (5mg/kg) was injected subcutaneously daily for 4weeks. Changes in glucose homeostasis, energy metabolism and brown adipose tissue (BAT) function were assessed. Results: The STZ mice had elevated blood glucose and reduced plasma FGF21 levels, impaired glucose uptake in the BAT, and BAT mitochondria with absent or swollen cristae and fewer lipid vacuoles. LY2405319 significantly reduced blood glucose levels and this was associated with increased BAT glucose uptake and changes in gene expression and morphology, indicating improved mitochondrial lipid metabolism in the BAT. Importantly, the ability of LY2405319 to lower blood glucose in STZ mice was compromised after removing interscapular BAT. Conclusions: Our results show that LY2405319 reduces blood glucose levels in insulin-deficient diabetes by improving BAT metabolism. Additional studies investigating the therapeutic potential of FGF21 for the treatment of type 1 diabetes are warranted.",
keywords = "Antidiabetic drug, Glucose uptake, Type 1 diabetes",
author = "Kim, {J. H.} and Bae, {K. H.} and Choi, {Y. K.} and Y. Go and M. Choe and Jeon, {Y. H.} and Lee, {H. W.} and Koo, {S. H.} and Perfield, {J. W.} and Robert Harris and Lee, {I. K.} and Park, {Keun Gyu}",
year = "2015",
month = "2",
day = "1",
doi = "10.1111/dom.12408",
language = "English",
volume = "17",
pages = "161--169",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin-induced insulin-deficient diabetic mice by restoring brown adipose tissue function

AU - Kim, J. H.

AU - Bae, K. H.

AU - Choi, Y. K.

AU - Go, Y.

AU - Choe, M.

AU - Jeon, Y. H.

AU - Lee, H. W.

AU - Koo, S. H.

AU - Perfield, J. W.

AU - Harris, Robert

AU - Lee, I. K.

AU - Park, Keun Gyu

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Aim: To investigate the effects of LY2405319, an analogue of fibroblast growth factor 21 (FGF21), on glucose homeostasis in streptozotocin (STZ)-induced insulin-deficient mice (STZ mice). Methods: Nine-week-old male C57BL/6J mice were administered a single intraperitoneal injection of STZ (150mg/kg). Oneweek later, after confirmation of hyperglycaemia, saline or LY2405319 (5mg/kg) was injected subcutaneously daily for 4weeks. Changes in glucose homeostasis, energy metabolism and brown adipose tissue (BAT) function were assessed. Results: The STZ mice had elevated blood glucose and reduced plasma FGF21 levels, impaired glucose uptake in the BAT, and BAT mitochondria with absent or swollen cristae and fewer lipid vacuoles. LY2405319 significantly reduced blood glucose levels and this was associated with increased BAT glucose uptake and changes in gene expression and morphology, indicating improved mitochondrial lipid metabolism in the BAT. Importantly, the ability of LY2405319 to lower blood glucose in STZ mice was compromised after removing interscapular BAT. Conclusions: Our results show that LY2405319 reduces blood glucose levels in insulin-deficient diabetes by improving BAT metabolism. Additional studies investigating the therapeutic potential of FGF21 for the treatment of type 1 diabetes are warranted.

AB - Aim: To investigate the effects of LY2405319, an analogue of fibroblast growth factor 21 (FGF21), on glucose homeostasis in streptozotocin (STZ)-induced insulin-deficient mice (STZ mice). Methods: Nine-week-old male C57BL/6J mice were administered a single intraperitoneal injection of STZ (150mg/kg). Oneweek later, after confirmation of hyperglycaemia, saline or LY2405319 (5mg/kg) was injected subcutaneously daily for 4weeks. Changes in glucose homeostasis, energy metabolism and brown adipose tissue (BAT) function were assessed. Results: The STZ mice had elevated blood glucose and reduced plasma FGF21 levels, impaired glucose uptake in the BAT, and BAT mitochondria with absent or swollen cristae and fewer lipid vacuoles. LY2405319 significantly reduced blood glucose levels and this was associated with increased BAT glucose uptake and changes in gene expression and morphology, indicating improved mitochondrial lipid metabolism in the BAT. Importantly, the ability of LY2405319 to lower blood glucose in STZ mice was compromised after removing interscapular BAT. Conclusions: Our results show that LY2405319 reduces blood glucose levels in insulin-deficient diabetes by improving BAT metabolism. Additional studies investigating the therapeutic potential of FGF21 for the treatment of type 1 diabetes are warranted.

KW - Antidiabetic drug

KW - Glucose uptake

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84921325509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921325509&partnerID=8YFLogxK

U2 - 10.1111/dom.12408

DO - 10.1111/dom.12408

M3 - Article

VL - 17

SP - 161

EP - 169

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 2

ER -